A Potential Renewed Use of Very Heavy Ions for Therapy: Neon Minibeam Radiation Therapy.

heavy ion therapy hypoxic tumors minibeam radiation therapy normal tissue toxicity

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
17 Mar 2021
Historique:
received: 24 02 2021
revised: 09 03 2021
accepted: 12 03 2021
entrez: 3 4 2021
pubmed: 4 4 2021
medline: 4 4 2021
Statut: epublish

Résumé

(1) Background: among all types of radiation, very heavy ions, such as Neon (Ne) or Argon (Ar), are the optimum candidates for hypoxic tumor treatments due to their reduced oxygen enhancement effect. However, their pioneering clinical use in the 1970s was halted due to severe side effects. The aim of this work was to provide a first proof that the combination of very heavy ions with minibeam radiation therapy leads to a minimization of toxicities and, thus, opening the door for a renewed use of heavy ions for therapy; (2) Methods: mouse legs were irradiated with either Ne MBRT or Ne broad beams at the same average dose. Skin toxicity was scored for a period of four weeks. Histopathology evaluations were carried out at the end of the study; (3) Results: a significant difference in toxicity was observed between the two irradiated groups. While severe da-mage, including necrosis, was observed in the broad beam group, only light to mild erythema was present in the MBRT group; (4) Conclusion: Ne MBRT is significantly better tolerated than conventional broad beam irradiations.

Identifiants

pubmed: 33802835
pii: cancers13061356
doi: 10.3390/cancers13061356
pmc: PMC8002595
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

PLoS One. 2020 Jun 22;15(6):e0229053
pubmed: 32569277
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1126-1136
pubmed: 31461675
Phys Med Biol. 2016 Jun 21;61(12):4551-63
pubmed: 27224547
Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14203-8
pubmed: 16162670
Sci Rep. 2018 Nov 7;8(1):16479
pubmed: 30405188
Mutat Res Genet Toxicol Environ Mutagen. 2015 Nov;793:41-7
pubmed: 26520371
Radiother Oncol. 2004 Dec;73 Suppl 2:S41-9
pubmed: 15971308
Phys Med Biol. 2010 Sep 21;55(18):5557-67
pubmed: 20808027
J Radiat Res. 1991 Jun;32(2):175-80
pubmed: 1658319
Med Phys. 2012 Mar;39(3):1234-8
pubmed: 22380354
Cancers (Basel). 2020 Oct 17;12(10):
pubmed: 33080914
Med Phys. 2017 Oct;44(10):5445-5449
pubmed: 28710866
Nat Commun. 2017 Mar 01;8:14684
pubmed: 28248284
Sci Rep. 2017 Dec 11;7(1):17295
pubmed: 29229965
Proteomes. 2013 Jul 10;1(2):40-69
pubmed: 28250398
Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1171-85
pubmed: 7713781
Radiother Oncol. 2015 May;115(2):279-83
pubmed: 25981129
Technol Cancer Res Treat. 2003 Oct;2(5):427-36
pubmed: 14529307
Int J Nanomedicine. 2018 Oct 04;13:6049-6058
pubmed: 30323592
Int J Radiat Oncol Biol Phys. 1977;3:103-8
pubmed: 614310
Radiat Prot Dosimetry. 2001;94(3):275-80
pubmed: 11487811
Int J Radiat Oncol Biol Phys. 2016 May 1;95(1):234-241
pubmed: 26692028
Int J Radiat Oncol Biol Phys. 1994 Jul 1;29(4):647-55
pubmed: 8040010
Int J Radiat Biol. 2014 Dec;90(12):1119-24
pubmed: 24923475
Cancer Res. 2007 May 1;67(9):4295-302
pubmed: 17483342
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9709-14
pubmed: 16760251
Clin Transl Radiat Oncol. 2021 Jan 08;27:44-49
pubmed: 33511291
J Bone Oncol. 2016 Jan 28;5(1):22-9
pubmed: 26998423
Med Phys. 2015 Oct;42(10):5928-36
pubmed: 26429267
Int J Radiat Oncol Biol Phys. 2019 Jun 1;104(2):266-271
pubmed: 30703513
Radiat Res. 2020 Dec 1;194(6):715-723
pubmed: 32991712
Med Phys. 2011 Sep;38(9):5012-20
pubmed: 21978045
Exp Hematol. 2007 Apr;35(4 Suppl 1):69-77
pubmed: 17379090
Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):e693-700
pubmed: 22270173
J Synchrotron Radiat. 2012 Jan;19(Pt 1):60-5
pubmed: 22186645
Med Phys. 2018 Jun;45(6):2620-2627
pubmed: 29633284
Radiat Res. 2015 Sep;184(3):314-21
pubmed: 26284420
PLoS One. 2010 Feb 03;5(2):e9028
pubmed: 20140254
Cancer Res. 1996 Mar 1;56(5):941-3
pubmed: 8640781
Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):761-9
pubmed: 2004953
Sci Rep. 2020 Aug 11;10(1):13511
pubmed: 32782370
Sci Rep. 2017 Oct 31;7(1):14403
pubmed: 29089533

Auteurs

Yolanda Prezado (Y)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.
Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Ryochi Hirayama (R)

Department of Charged Particle Therapy Research, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.

Naruhiro Matsufuji (N)

Department of Charged Particle Therapy Research, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Department of Accelerator and Medical Physics, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.

Taku Inaniwa (T)

Department of Charged Particle Therapy Research, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Department of Accelerator and Medical Physics, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.

Immaculada Martínez-Rovira (I)

Ionizing Radiation Research Group, Physics Department, Universitat Autònoma de Barcelona (UAB), E-08193 Cerdanyola del Vallès, Spain.

Olivier Seksek (O)

Université Paris-Saclay, CNRS/IN2P3, Université de Paris, IJCLab, Pole Santé, 91405 Orsay, France.

Annaïg Bertho (A)

Institut Curie, Université PSL, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.
Université Paris-Saclay, CNRS UMR3347, Inserm U1021, Signalisation Radiobiologie et Cancer, 91400 Orsay, France.

Sachiko Koike (S)

Department of Charged Particle Therapy Research, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Department of Accelerator and Medical Physics, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.

Dalila Labiod (D)

Experimental Radiotherapy Platform, Translational Research Department, Institut Curie, Université Paris Saclay, 91400 Orsay, France.

Frederic Pouzoulet (F)

Experimental Radiotherapy Platform, Translational Research Department, Institut Curie, Université Paris Saclay, 91400 Orsay, France.

Laura Polledo (L)

AnaPath Services GmbH, Hammerstrasse 49, 4410 Liestal, Switzerland.

Nils Warfving (N)

AnaPath Services GmbH, Hammerstrasse 49, 4410 Liestal, Switzerland.

Aléthéa Liens (A)

AnaPath Services GmbH, Hammerstrasse 49, 4410 Liestal, Switzerland.

Judith Bergs (J)

Department of Radiology Charité-Universitätsmedizin Berlin, CCM Charitéplatz 1, 10117 Berlin, Germany.

Takashi Shimokawa (T)

Department of Charged Particle Therapy Research, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.
Department of Accelerator and Medical Physics, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology, Chiba 263-8555, Japan.

Classifications MeSH